Abeona Therapeutics (NASDAQ:ABEO) Given Buy Rating at HC Wainwright

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $15.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 150.84% from the company’s […]

Leave a Reply

Your email address will not be published.

Previous post Equinor ASA (NYSE:EQNR) Upgraded by Barclays to “Overweight” Rating
Next post Cartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at Needham & Company LLC